Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Pharma Presents Robust Pipeline And Outlines New R&D Structure

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

In a wide-ranging presentation to Wall Street, the company highlights key new products in development and an R&D strategy built around five therapeutic areas

You may also be interested in...

Here A Lawsuit, There A Lawsuit

Verus charges AstraZeneca with breach of contract: AstraZeneca was sued for $1.28 billion in New York state court on May 25 by Verus Pharmaceuticals, which accused the drug maker of backing out of a deal to develop a pediatric asthma medication and, instead, striking a deal with Map Pharmaceuticals, which was developing a similar drug. AstraZeneca and Verus planned a new formulation of the active ingredient in AstraZeneca's Pulmicort asthma drug that would be easier to use and work faster. In its lawsuit, Verus claimed AstraZeneca agreed to pursue development at least until a meeting with the Food and Drug Administration at the end of Phase II clinical trials. Instead, Verus charged, AstraZeneca backed out of the deal in December 2008 without scheduling a meeting and suddenly struck a similar arrangement with Map. Verus is seeking $280 million in compensatory damages and $1 billion in punitive damages from AstraZeneca, which the smaller company accuses of being motivated by "unmitigated greed." AstraZeneca denied the charges

Xarelto Action Letter No Surprise; But Does FDA Want Data, REMS Or Both?

As anticipated, FDA answered Johnson & Johnson/Bayer's NDA for anticoagulant Xarelto (rivaroxaban) with a complete response letter May 28

Xarelto “Complete Response” No Surprise, But Does FDA Want Data, A REMS Or Both?

Approval could be pushed out to 2010 if the agency wants to review data from the ATLAS study, which completed too late to get into the NDA package.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts